Details of the Drug
General Information of Drug (ID: DM2QPHE)
| Drug Name |
5-bromo-1H-indazole
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
5-bromo-1H-indazole; 5-Bromoindazole; 53857-57-1; 5-Bromo-2H-indazole; 1h-indazole, 5-bromo-; 465529-55-9; CHEMBL16425; 5-Bromo-1H-indazole, 97%; 5-brom-1h-indazol; MLS000088501; 5-bromoazaindole; 5-bromo-indazole; 5- Bromoindazole; 5-bromo-azaindole; 5-bromo-1hindazole; AC1LFXVY; 4-Nitrotrityl chloride; PubChem15628; 5-bromo-1 h-indazole; ACMC-209lal; 5-bromanyl-1H-indazole; 2H-Indazole, 5-bromo-; SCHEMBL5562; AC1Q1H9U; KSC269G3N; cid_761929; AMBZ0279; CTK1G9336; DTXSID50354020; HID1020; STVHMYNPQCLUNJ-UHFFFAOYSA-N; MolPort-029-084-055
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 197.03 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2.9 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


